Cookie Laws within the EU Allow Cookies
Meet the Team at CV Pharma
Meet the Team at CV Pharma Limited
an innovative pharmaceutical company
Welcome Meet the Team Trade Enquiries Private Enquiries Investors Useful Links Contact Us
   
 
Meet the team at CV Pharma Limited  
     
 
The team at CV Pharma comprises of a number of individuals with specialist expertise and successful track records in developing business strategies for early stage companies, the UK and international medical research and development and pet insurance sectors who have come together to develop CV Pharma Limited.


Clare Morriss
Clare implements her strong organisational skills in dynamic, change management, client service and corporate experience working for Satellite Information Services. She centralises the CV Pharma team and manages the day to day running of the company.

Elena Wilde MSc KCL
Scientific Adviser
Elena completed her masters in Clinical Trial planning at King’s College London, where she is also currently completing her PhD. She leads the team on our scientific matters, particularly to do with our proposed clinical trials and clinical development plans.

Roger Wood FCA BSc
Chairman
Roger has skills in creating business models, implementing strategies, and raising finance in different scales of business from start-ups through to FTSE 100 companies in a variety of industrial and financial sectors. He has been a significant investor as well as a leading executive in the creation of new businesses as start-ups and as early stage companies during the past 15 years.

Roger was finance director for FTSE 100 and 350 companies including Burmah Oil PLC, George Wimpey PLC and the Guthrie Corporation, developing business strategies to maximise shareholder value.

Roger invested in start-ups and early stage companies, being a leading executive in the creation of Vinopolis, a wine entertainment attraction (sold for £40m+), and Fundamental Data, a closed-end investment trusts database (sold for £11m). He chaired Premier Asset Management plc, a quoted fund management company, which had to be turned around from losses to profits, increasing funds from £0.5 billion to £2.0 billion, and sold for £52m. All these companies have seen the substantial creation of shareholder value with investors successfully selling out during Roger’s executive employment.


External Advisors

Dr Roger Oakes
Consultant
Dr Roger Oakes is a fellow of the Royal Society of Medicine and a member of the Association for Human Pharmacology in the Pharmaceutical Industry. He has throughout his career specialised in drug development, from a regulatory and technical perspective. He was President of Pharmaceutical Development at Senetek plc and a Main Board Director from September 1995 to May 1998. He was managing Director of Leicester Clinical Research Centre for five years to February 1995 and for two years to February 2002. Earlier in his career he was Product Development Director of Tillotts Laboratories (now part of Pfizer via Pharmacia and Upjohn) for seven years until January 1990.

Simon Rawlings
Communications
Simon coordinates communications with private and trade customers and the company’s IT facilities.

Paul Ripley
BVM&S, MRCVS
A veterinary surgeon; then with Wellcome carrying out safety testing for vaccines; followed by Rhone-Merieux and Novartis responsible for regulatory development. Experienced in animal health product development and registration, both pharmaceutical and immunological, and in the conduct of veterinary clinical trials.

Prof Sebestény
BVSc, Dip.Bact., MRCVS
Qualified as a veterinary surgeon in 1960 from Bristol University and has been in practice, both full and part time ever since. Since 1964 he has also been the veterinary supervisor of laboratory animals at the Imperial Cancer Research Fund (now CR UK), where he was until 2008 a consultant veterinary pathologist. In addition he has been the "named vet" at the Ludwig Institute of Cancer Research since 1988. Andor Sebesteny has published over 30 papers in health control and cancer research, and has presented papers at over 60 National and International meetings. He has been appointed Honorary Professor of laboratory animal science at Budapest Veterinary University.

David Seel
Entrepreneur in the Pet Insurance sector
David has skills in creating and implementing business strategies from start-up to multi-million-pound turnover companies in the marketing of insurance products via the veterinary market and by FTSE 100 Financial Institutions and Retailers. David has worked as a Director of Hogg Robinson London Limited then a Director of Swire Fraser Limited, Lloyd’s Insurance Brokers. David formed Thornside Limited in 1999 as a specialist Pet Insurance administrator and Broker. Thornside was the largest behind the brand pet insurance administrator and broker in the UK, with a premium income of in excess of £130 million. It acted for over 40 of the leading UK brands, including Sainsbury’s, John Lewis, and Pets at Home. David was appointed Chairman of the ABI Pet Insurance Committee in 2010.

Dr Ros Taylor
MBE MA MB BChir MRCGP
Trained in medicine at Cambridge University and Westminster Hospital, London and qualified as a doctor in 1980. She initially pursued a career as a GP in the Lake District but became increasingly interested in the unique challenges that families face when a terminal illness is diagnosed. She left general practice for a career in palliative and hospice medicine and has been Clinical Director of the Hospice UK and is a Palliative Cancer Physician at the Royal Marsden, London.

Professor Peter Vajdovich
DVM, PhD, Dipl. of ECVCP
Peter is the leading veterinary oncologist at the University of Veterinary Medicine, Budapest, Hungary.
 
     
 
Registered Office: CV Pharma Limited, High Leybourne, Hascombe, Godalming, Surrey GU8 4AD, UK. Company Reg., No. 03697835
Designed by The Bureau